Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
November 2017 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the November BNF eNewsletter.
Eight new drug monographs have been added to the BNF in the last month, including - asfotase alfa, glecaprevir with pibrentasvir, inotuzumab ozogamicin, patiromer calcium, sarilumab, and tryptophan.

This issue includes dose changes for ustekinumab, as well as new guidance on the management of spondyloarthritis. We have included updated MHRA advice on loperamide: reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse. You will also find NICE technology appraisals for baricitinib, cetuximab, eluxadoline, obinutuzumab, olaratumab, and pemetrexed.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
How to purchase BNF More >  
Price reminder More >  
Drug safety update More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 74 - BNFC 2017-2018
BNF Update
Beclometasone with formoterol and glycopyrronium: new drug monograph
For further information, see beclometasone with formoterol and glycopyrronium.
Glecaprevir with pibrentasvir: new drug monograph
For further information, see glecaprevir with pibrentasvir.
Inotuzumab ozogamicin: new drug monograph
For further information, see inotuzumab ozogamicin.
Patiromer calcium: new drug monograph
For further information, see patiromer calcium.
Sarilumab: new drug monograph
For further information, see sarilumab
Dose changes
Ustekinumab [dose for plaque psoriasis in patients with body-weight over 100kg]
For further information, see ustekinumab.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Baricitinib for moderate-to-severe rheumatoid arthritis
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Eluxadoline for treating irritable bowel syndrome with diarrhoea
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Other changes
To review other changes in the BNF, click on changes.
BNF for Children Update
Dose changes
Ustekinumab [moderate-to-severe plaque psoriasis]
For further information, see ustekinumab.
Other changes
To review other changes in BNF for Children, click on changes.
BNF BNF for Children Update
Loperamide: reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse (MHRA advice)
For further information, see loperamide.
Asfotase alfa: new drug monograph
For further information, see asfotase alfa.
I News
Reminder - help from CPPE with BNF 74
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 74. It comprises 10 practical case studies, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the September 2017 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
I Monthly price update reminder
Prices of all branded medicinal products in the BNF and BNFC are now updated monthly. Prices of generic preparations of medicinal products are updated every 2-4 months, to coincide with print editions of BNF and BNF for Children. The BNF team keeps price information up to date using data sourced from the NHS dictionary of medicines and devices (dm+d).
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2017 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2017 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.